Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis

Figures & data

Table 1. Characteristics of included studies.

Descriptions of included studies						Outcomes available for analysis
N	Study	Funding	Design	Main criteria	inclusion N	Definition of remission	Definition of response		Induction of Remission wk	Induction of Response wk
1	Chen 2020	Yes	RCT	CDAI＞220 Anti-TNF naive	102	CDA＜150	ΔCDAI＞70	ΔCDAI＞100	4	4
2	Hanauer 2006	Yes	RCT	CDAI＞220 Anti-TNF naive	225	CDA＜150	ΔCDAI＞70	ΔCDAI＞100	4	4
3	Sandborn 2007	Yes	RCT	CDAI 220–450, IFX resistant	159	CDA＜150	ΔCDAI＞70	ΔCDAI＞100	4	4
4	Watanabe 2012	Yes	RCT	CDAI＞220	67	CDA＜150	ΔCDAI＞70	ΔCDAI＞100	4	4

Abbreviations: RCT: randomized controlled studies; and CDAI: Crohn’s disease activity index; IFX: Infliximab.

Figure 1. Flowchart of study selection.

Figure 2. Pooled risk ratios for patients with solid cancer compared with healthy controls after a first dose of COVID-19.

Figure 3. Pooled risk ratios for seroconversion among patients with solid cancer compared with healthy controls.

Figure 4. Subgroup analysis of vaccine type among patients with solid cancer patients after first dose.

Figure 5. Subgroup analysis of vaccine type among patients with solid cancer patients after second dose.